HM Payson & Co. Sells 23,204 Shares of Pfizer Inc. $PFE

HM Payson & Co. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 4.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 475,557 shares of the biopharmaceutical company’s stock after selling 23,204 shares during the quarter. HM Payson & Co.’s holdings in Pfizer were worth $12,117,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of PFE. Brighton Jones LLC grew its stake in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC increased its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares in the last quarter. WPG Advisers LLC bought a new stake in shares of Pfizer in the first quarter valued at approximately $35,000. Magnetar Financial LLC bought a new position in Pfizer in the 1st quarter worth approximately $1,823,000. Finally, Vident Advisory LLC grew its stake in Pfizer by 761.7% in the 1st quarter. Vident Advisory LLC now owns 80,414 shares of the biopharmaceutical company’s stock valued at $2,038,000 after buying an additional 71,082 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

PFE has been the subject of several analyst reports. The Goldman Sachs Group restated a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research note on Wednesday, November 5th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Bank of America lowered their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $28.06.

Pfizer Stock Performance

NYSE PFE opened at $25.10 on Monday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The company has a market capitalization of $142.68 billion, a P/E ratio of 14.59 and a beta of 0.46. The company has a fifty day moving average of $25.16 and a 200-day moving average of $24.89.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The firm had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s dividend payout ratio is currently 100.00%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.